摘要
目的探讨利奈唑胺治疗重症肺炎的临床疗效及安全性。方法我院呼吸科2009年10月17日至2010年12月31日收治的重症肺炎患者68例,采用单盲、随机对照试验研究。分为治疗组35例,对照组33例。治疗组给予利奈唑胺600 mg静脉滴注,12 h/(次.d),疗程7～14 d;对照组予盐酸万古霉素500 mg,8 h/(次.d),疗程7～14 d。观察两组患者治疗总有效率、显效时间、细菌清除率及不良反应。结果治疗组、对照组有效率分别为88.6%(31/35)、87.9%(29/33),差异无统计学意义(P>0.05);细菌清除率分别为87.5%(28/32)、84.6%(22/26),差异无统计学意义(P>0.05);不良反应发生率分别为2.8%(1/35)、12.1%(4/33),差异有统计学意义(P<0.05)。结论利奈唑胺治疗G+菌菌株感染的重症肺炎疗效确切,安全性高。
Objective To investigate the effect and safety of linezolid in the treatment of severe pneumonia.Methods 68 cases with severe pneumonia in Pneumology Department of our hospital from October 17 in 2009 to December 31 in 2010 were analyzed retrospectively by single blind experiment and randomized control trial.There were 35 cases in the treatment group and 33 cases in the control group.The treatment group was administered with linezolid：600 mg,iv,12 h/d,lasting for 7~14 days;the control group was treated with vancomycin：500 mg,iv,8 h/d,lasting for the same time.Changes of total effective rate,time to onset,bacteria clearance and side effects were analyzed.Results There was no significant difference（P0.05）between treatment group and control group in effective rate（88.6%,31/35;87.9%,29/33）and bacteria clearance（87.5%,84.6%）.But there was significant difference（P0.05）between them on the rate of side effects（2.8%,1/35;12.1%,4/33）.Conclusion Linezolid is safe and effective in the treatment of severe pneumonia infected by Gram positive cocci.
出处
《实用药物与临床》
CAS
2011年第5期376-379,共4页
Practical Pharmacy and Clinical Remedies
基金
国家科技支撑计划课题(2007BAI24B04)
中华医学会基金项目(070103200400
07010250033
08020680146)
辽宁省教育厅(2009A760)
关键词
利奈唑胺
G+菌
重症肺炎
Linezolid
Gram positive cocci
Severe pneumonia
